文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

2023年10月至2024年4月期间,20个欧洲国家通过政府和非政府提供途径获取暴露前预防(PrEP)的男男性行为者(MSM)中口服PrEP的使用情况及使用长效PrEP方案的意向。

Oral PrEP use and intention to use long-acting PrEP regimens among MSM accessing PrEP via governmental and non-governmental provision pathways, 20 European countries, October 2023 to April 2024.

作者信息

Wang Haoyi, Adriaque Lozano Alejandro, Kolstee Johann, Zimmermann Hanne Ml, Tosh Jonathan, Schroeder Melanie, Appiah Ama, Jonas Kai J

机构信息

Viroscience department, Erasmus Medical Centre, Rotterdam, The Netherlands.

Department of Work and Social Psychology, Maastricht University, Maastricht, The Netherlands.

出版信息

Euro Surveill. 2025 Aug;30(34). doi: 10.2807/1560-7917.ES.2025.30.34.2500122.


DOI:10.2807/1560-7917.ES.2025.30.34.2500122
PMID:40878701
Abstract

BACKGROUNDPre-exposure prophylaxis (PrEP) provision routes across Europe differ notably between governmental and non-governmental pathways. The introduction of long-acting (LA)-PrEP may further diversify provision dynamics.AIMWe investigated disparities in PrEP access and whether access pathways determine oral PrEP use patterns and LA-PrEP intention among PrEP-experienced men who have sex with men (MSM).METHODSUsing data from 7,505 PrEP-experienced MSM from a cross-sectional survey (PROTECT; 20 European countries, October 2023-April 2024), we used latent class analysis (LCA) to identify MSM's latent socioeconomic positions (SEPs), and logistic regression to compare the likelihood of accessing governmental/non-governmental pathways, and compare oral PrEP adherence, discontinuation and LA-PrEP intention between governmental/non-governmental pathways.RESULTSMost MSM accessed PrEP via governmental pathways (n = 6,671; 88.9%), 11.1% (n = 834) used non-governmental pathways. The LCA identified three groups: employed MSM with more advantaged SEPs, younger MSM with less advantaged SEPs, and older MSM with more advantaged SEPs. Compared with the first group, younger MSM with less advantaged SEPs were significantly more likely to access PrEP via non-governmental pathways (aOR = 1.27; 95% confidence interval (CI): 1.04-1.55). Accessing PrEP via non-governmental pathways was associated with suboptimal adherence (aOR = 1.28; 95% CI: 1.03-1.58), discontinuation (aOR = 3.55; 95% CI: 2.99-4.21), but also higher LA-PrEP intention (aOR = 1.28; 95% CI: 1.06-1.56).CONCLUSIONSInequalities exist in PrEP access among MSM in Europe. While non-governmental pathways offer opportunities to engage MSM with less advantaged SEPs, oral PrEP use patterns via this pathway were not optimal. Tailored efforts should ensure that PrEP is accessible and affordable to enhance current use and prepare for future LA-PrEP modalities.

摘要

背景 在欧洲,暴露前预防(PrEP)的提供途径在政府和非政府渠道之间存在显著差异。长效(LA)-PrEP的引入可能会使提供动态进一步多样化。 目的 我们调查了有PrEP使用经验的男男性行为者(MSM)在PrEP获取方面的差异,以及获取途径是否决定口服PrEP的使用模式和对LA-PrEP的意向。 方法 利用一项横断面调查(PROTECT;20个欧洲国家,2023年10月至2024年4月)中7505名有PrEP使用经验的MSM的数据,我们使用潜在类别分析(LCA)来确定MSM的潜在社会经济地位(SEP),并使用逻辑回归来比较通过政府/非政府途径获取PrEP的可能性,以及比较政府/非政府途径之间口服PrEP的依从性、停药情况和对LA-PrEP的意向。 结果 大多数MSM通过政府途径获取PrEP(n = 6671;88.9%),11.1%(n = 834)使用非政府途径。LCA确定了三组:社会经济地位更优越的就业MSM、社会经济地位较不优越的年轻MSM以及社会经济地位更优越的年长MSM。与第一组相比,社会经济地位较不优越的年轻MSM通过非政府途径获取PrEP的可能性显著更高(调整后比值比[aOR]=1.27;95%置信区间[CI]:1.04 - 1.55)。通过非政府途径获取PrEP与依从性欠佳(aOR = 1.28;95% CI:1.03 - 1.58)、停药(aOR = 3.55;95% CI:2.99 - 4.21)相关,但对LA-PrEP的意向也更高(aOR = 1.28;95% CI:1.06 - 1.56)。 结论 欧洲MSM在PrEP获取方面存在不平等。虽然非政府途径为社会经济地位较不优越的MSM提供了参与机会,但通过该途径的口服PrEP使用模式并不理想。应采取有针对性的措施,确保PrEP可及且价格合理,以增加当前的使用并为未来的LA-PrEP模式做好准备。

相似文献

[1]
Oral PrEP use and intention to use long-acting PrEP regimens among MSM accessing PrEP via governmental and non-governmental provision pathways, 20 European countries, October 2023 to April 2024.

Euro Surveill. 2025-8

[2]
Awareness and intention to use event-driven and long-acting injectable pre-exposure prophylaxis among adolescent and young men who have sex with men and transgender women in Brazil: a cross-sectional study.

J Int AIDS Soc. 2025-7

[3]
Location Preferences for Accessing Long-Acting Injectable Pre-Exposure Prophylaxis (LA-PrEP) Among Men Who Have Sex With Men (MSM) Currently on Daily Oral PrEP.

J Int Assoc Provid AIDS Care. 2024

[4]
Intention to Use Pre-Exposure Prophylaxis Among Age Groups of Brazilian Men Who Have Sex With Men: National Cross-Sectional Study.

JMIR Public Health Surveill. 2025-7-8

[5]
Differences between men who have sex with men that use drugs and engage in chemsex and those who do not engage in chemsex in the French ANRS-PREVENIR cohort: the need to rethink harm reduction services.

Subst Abuse Treat Prev Policy. 2025-8-25

[6]
The Disparities of PrEP Adherence Among Men Who Have Sex With Men Between the Global South and the Global North: An Updated Determinantal Global Meta-Analysis.

J Acquir Immune Defic Syndr. 2025-5-1

[7]
Optimising HIV pre-exposure prophylaxis and testing strategies in men who have sex with men in Australia, Thailand, and China: a modelling study and cost-effectiveness analysis.

Lancet Glob Health. 2024-2

[8]
Willingness to Use Long-Acting Injectable Cabotegravir and Associated Factors Among Men Who Have Sex with Men in Guangxi, China.

Arch Sex Behav. 2024-7

[9]
Men's Voices on Long-Acting Pre-Exposure Prophylaxis Delivery Modalities: Acceptability and Preferences Among Cisgender Men and Men Who Have Sex With Men in South Africa.

J Acquir Immune Defic Syndr. 2025-5-1

[10]
Impact of changing pre-exposure prophylaxis regimens on retention among men who have sex with men in Hanoi, Vietnam (2020-2023): a cohort study.

J Int AIDS Soc. 2025-7

本文引用的文献

[1]
Epidemiological impact and cost-effectiveness analysis of PrEP provision expansion among MSM in the Netherlands.

J Int AIDS Soc. 2025-6

[2]
The Disparities of PrEP Adherence Among Men Who Have Sex With Men Between the Global South and the Global North: An Updated Determinantal Global Meta-Analysis.

J Acquir Immune Defic Syndr. 2025-5-1

[3]
Policy Recommendations to Support Equitable Access to Long-Acting Injectables for Human Immunodeficiency Virus Prevention and Treatment: A Policy Paper of the Infectious Diseases Society of America and the HIV Medicine Association.

Clin Infect Dis. 2025-1-28

[4]
Missed opportunities for early HIV diagnosis in Greece: The MORFEAS study, 2019 to 2021.

Euro Surveill. 2024-11

[5]
Likelihood of HIV and recent bacterial sexually transmitted infections among transgender and non-binary individuals in 20 European countries, October 2023 to April 2024.

Euro Surveill. 2024-11

[6]
Twice-Yearly Lenacapavir or Daily F/TAF for HIV Prevention in Cisgender Women.

N Engl J Med. 2024-10-3

[7]
Intention and preference to use long-acting injectable PrEP among MSM in the Netherlands: a diffusion of innovation approach.

AIDS Care. 2024-7

[8]
HIV pre-exposure prophylaxis services, provision, and delivery in the European treatment network of HIV, hepatitis and global emerging infectious diseases (NEAT ID).

HIV Med. 2024-3

[9]
Population-level impact of expanding PrEP coverage by offering long-acting injectable PrEP to MSM in three high-resource settings: a model comparison analysis.

J Int AIDS Soc. 2023-7

[10]
Preparing for long-acting PrEP delivery: building on lessons from oral PrEP.

J Int AIDS Soc. 2023-7

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索